Cited by 1,155Multiple Myeloma Research and TreatmentsBone health and treatmentsMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Open access

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, Harousseau, Jean-Luc·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114138

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114138

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation

Show all 24 references

Sorted by citations

Items 401–500 of 1,000

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
Katodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Sidiqi, M. H., Aljama, M. A., Riaz, I. B., Dispenzieri, A. A., Muchtar, E., Buadi, F. K., Warsame, R. M., Lacy, M. Q., Dingli, D., Leung, N., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0147-7 · Cited by 20
An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission
Biavati, L., Huff, C. A., Ferguson, A. K., Sidorski, A., Stevens, M. A., Rudraraju, L., Zucchinetti, C., Ali, S. A., Imus, P. H., Gocke, C. B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1916 · Cited by 20
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 20
A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature
Ragupathi, L., Najfeld, V., Chari, A., Petersen, B. E., Jagannath, S., & Mascarenhas, J. O. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.010 · Cited by 20
Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma
Shin, H., Kım, K., Lee, J. W., Song, M., Lee, J., Lee, H. S., Lee, W. S., Kim, S. J., & Chung, J. S. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12377 · Cited by 20
The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme
Favier, R., & Crépin, S. (2018) · Clinical Trials · doi:10.1177/1740774518760565 · Cited by 19
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Gozzetti, A., Raspadori, D., Bacchiarri, F., Sicuranza, A., Pacelli, P., Ferrigno, I., Tocci, D., & Bocchia, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030120 · Cited by 19
Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
Gerke, M. B., Christodoulou, I., & Karantanos, T. (2023) · Cancers · doi:10.3390/cancers15153815 · Cited by 19
Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques
Biran, N., Ely, S. A., & Chari, A. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0237-y · Cited by 19
Phase I‐ II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
Reece, D. E., Masih‐Khan, E., Atenafu, E. G., Jimenez-Zepeda, V. H., Anglin, P., Chen, C. I., Kukreti, V., Mikhael, J. R., & Trudel, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13100 · Cited by 19
Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
Wirk (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1274w · Cited by 19
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
Mateos, M. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70007-3 · Cited by 19
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes ( C row– F ukase) syndrome: Diagnostic criteria and treatment perspectives
Misawa, S., & Kuwabara, S. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12052 · Cited by 19
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
Sivaraj, D., Bacon, W., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Sullivan, K. M., Kang, Y., Li, Z., Chao, N. J. A., & Gasparetto, C. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.208 · Cited by 19
The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study
Jónsdóttir, G., Lund, S. H., Björkholm, M., Turesson, I., Hultcrantz, M. L., Porwit‐MacDonald, A., Jethava, Y. S., Landgren, O., & Kristinsson, S. Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007930 · Cited by 19
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
Holstein, S. A., Avet‐Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.774 · Cited by 20
Self-citation
Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials
Gengenbach, L., Reinhardt, H., Ihorst, G., Ajayi, S., Dold, S. M., Köhler, M., Einsele, H., Duyster, J., Wäsch, R., & Engelhardt, M. M. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1448084 · Cited by 19
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Huang, J. J., Phillips, S. E., Byrne, M. T., Chinratanalab, W., Engelhardt, B. G., Goodman, S. A., Harrell, S. L., Jagasia, M., Kassim, A. A., Rawling, K. T., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0177-6 · Cited by 19
Increasing therapy‐related myeloid neoplasms in multiple myeloma
Fernández‐Caballero, M., Salmerón, D., Chirlaque, M. D., Chen‐Liang, T. H., Hurtado, A. M., García‐Malo, M. D., Ortuño, F. J., Roldán, V., Vicente, V., Jerez, A., et al. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13050 · Cited by 19
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
Thiéblemont, C., Howlett, S., Casasnovas, O., Mounier, N., Perrot, A., Morschhauser, F., Fruchart, C., Daguindau, N., Eygen, K. V., Obéric, L., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16300 · Cited by 20
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
Gay, F., Mina, R., Troia, R., & Bringhen, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827169 · Cited by 20
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma
García‐Muñoz, R., de Castro, D. R., Muñoz, A., & Rabasa, P. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.786072 · Cited by 19
Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies
Bonafede, M., Richhariya, A., Cai, Q., Josephson, N. C., McMorrow, D., Garfin, P. M., & Perales, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1364648 · Cited by 19
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Miguel, J. F. S., Gutierrez, M. A. E., Špıčka, I., Mateos, M., Song, K., Craig, M., Bladé, J., Hájek, R., Chen, C. I., Bacco, A. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185991 · Cited by 19
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes
Hu, B., Thall, P. F., Milton, D. R., Sasaki, K., Bashir, Q., Shah, N. D., Patel, K. K., Popat, U., Hosing, C. M., Nieto, Y. L., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485908 · Cited by 19
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 18
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Jones, J. R., Cairns, D. A., Menzies, T., Pawlyn, C., Davies, F. E., Sigsworth, R., Brioli, A., Jenner, M. W., Kaiser, M., Olivier, C., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102099 · Cited by 18
Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation
Quintana, A. S., Rull, P. R., Atienza, J. B., & Notario, C. (2013) · Nephrology · doi:10.1111/nep.12116 · Cited by 18
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance
Zamarin, D., Devlin, S. M., Arcila, M. E., Landau, H. J., Lesokhin, A. M., Lendvai, N. K., Chung, D. J., Chimento, D., Weltz, J., Babu, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.126 · Cited by 18
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy
Gonsalves, W. I., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Go, R. S., Leung, N., Kapoor, P., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.91 · Cited by 18
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 19
Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report
Walavalkar, V., Adey, D., Laszik, Z. G., & Jen, K. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.01.014 · Cited by 18
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
Ho, M., Zanwar, S., Kapoor, P., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Dingli, D., Baudi, F. K., Muchtar, E., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00548-7 · Cited by 18
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.353 · Cited by 18
Self-citation
Lenalidomide in Multiple Myeloma—A Practice Guideline
Chen, C., Baldassarre, F. G., Kanjeekal, S. M., Herst, J. A., Hicks, L. K., & Cheung, M. C. (2013) · Current Oncology · doi:10.3747/co.20.1252 · Cited by 19
Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response
Fukumoto, K., Fujisawa, M., Suehara, Y., Narita, K., Usui, Y., Takeuchi, M., & Matsue, K. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1121262 · Cited by 18
Hematopoietic Stem Cell Transplantation
Im, A., & Pavletic, S. Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00028-1 · Cited by 19
Elranatamab: a new promising BispAb in multiple myeloma treatment
Grosicki, S., Bednarczyk, M., & Kociszewska, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236303 · Cited by 17
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
Pasvolsky, O., Ghanem, S., Milton, D. R., Masood, A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N., Lin, P. Y., Ramdial, J., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.08.031 · Cited by 17
Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis
Alnasser, S. M., Alharbi, K. S., Almutairy, A. F., Almutairi, S. M., & Alolayan, A. M. (2023) · Cells · doi:10.3390/cells12242855 · Cited by 18
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Fonseca, R., Zhu, Y. X., Bruins, L. A., Ahmann, J., de Campos, C. B., Braggio, E., Chen, X., Arribas, M., Darvish, S. A., Welsh, S. J., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01215-x · Cited by 17
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
Ye, X., Huang, J., Pan, Q., & Li, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072635 · Cited by 17
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients
McCarthy, P. L., Einsele, H., Attal, M., & Giralt, S. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.878645 · Cited by 17
Self-citation
Maintenance Therapy for Multiple Myeloma
McCarthy, P. L., & Palumbo, A. P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.006 · Cited by 17
Biology and Treatment of Myeloma
Brioli, A., Melchor, L., Walker, B. A., Davies, F. E., & Morgan, G. J. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.06.011 · Cited by 18
Role of stem cell transplant and maintenance therapy in plasma cell disorders
McCarthy, P. L., & Holstein, S. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.504 · Cited by 17
Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
D’Souza, A., Zhang, M.-J., Huang, J., Fei, M., Pasquini, M. C., Hamadani, M., & Hari, P. (2017) · Leukemia · doi:10.1038/leu.2017.185 · Cited by 17
Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
Alhuraiji, A., Naqvi, K., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 19
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 17
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Cherniawsky, H. M., Kukreti, V., Reece, D. E., Masih‐Khan, E., McCurdy, A. B. R., Jimenez-Zepeda, V. H., Sébag, M., Song, K., White, D. J., Stakiw, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.259093 · Cited by 17
Risk and Response-Adapted Treatment in Multiple Myeloma
Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet‐Loiseau, H., Corre, J., & Perrot, A. (2020) · Cancers · doi:10.3390/cancers12123497 · Cited by 20
Self-citation
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 17
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili, S., Weisel, K. C., Bokemeyer, C., & Leypoldt, L. B. (2021) · Oncology Research and Treatment · doi:10.1159/000520504 · Cited by 17
Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
Nunnelee, J. S., Cottini, F., Zhao, Q., Faisal, M. S., Elder, P., Rosko, A. E., Bumma, N., Khan, A., Devarakonda, S. S., Benson, D. M., et al. (2022) · Cancers · doi:10.3390/cancers14092277 · Cited by 17
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low‐dose cyclophosphamide: a randomized comparison
Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Säily, M., Sankelo, M., Terävä, V., Putkonen, M., Kuittinen, T., Pelkonen, J., et al. (2016) · Transfusion · doi:10.1111/trf.13574 · Cited by 17
Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation
DeFilipp, Z. M., & Chen, Y. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.021 · Cited by 17
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Sahebi, F., Iacobelli, S., Sbianchi, G., Köster, L., Blaise, D., Remenyi, P. P., Russell, N. H., Ljungman, P. T., Kobbe, G., Apperley, J. F., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.006 · Cited by 17
Self-citation
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Goldschmidt, H., Dimopoulos, M. A., Rajkumar, S. V., Weisel, K. C., Moreau, P., Chng, W. J., Mikala, G., Cavo, M., Ramasamy, K., Suryanarayan, K., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0819-8 · Cited by 18
Self-citation
Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward
Ali, A. M., Dehdashti, F., DiPersio, J. F., & Cashen, A. F. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.007 · Cited by 17
DFT Study on the Interaction of Lenalidomide Anticancer Drug on the Surface of B12N12 Nanocluster
Sharifi, S., Sheikhi, M., Shаhаb, S., Kaviani, S., & Kumar, R. (2021) · Letters in Organic Chemistry · doi:10.2174/1570178618666211027102305 · Cited by 16
Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Burnette, B. L., Dispenzieri, A. A., Kumar, S. K., Harris, A. M., Sloan, J. A., Tilburt, J. C., Kyle, R. A., & Rajkumar, S. V. (2013) · Cancer · doi:10.1002/cncr.28340 · Cited by 16
Allogeneic hematopoietic stem cell transplantation for multiple myeloma
Koehne, G., & Giralt, S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328358f619 · Cited by 16
Emerging biological insights and novel treatment strategies in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., & Morabito, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.713345 · Cited by 16
The risk of secondary primary malignancies after therapy for multiple myeloma
Areethamsirikul, N., & Reece, D. E. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.974043 · Cited by 16
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors
Robison, N. J., Yeo, K. K., Berliner, A. P., Malvar, J., Sheard, M. A., Margol, A., Seeger, R. C., Rushing, T., Finlay, J. L., Sposto, R., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2791-y · Cited by 16
Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
Khan, A., Muzaffar, J., Murthy, H. S., Wingard, J. R., & Moreb, J. S. (2018) · Case Reports in Hematology · doi:10.1155/2018/9052314 · Cited by 16
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
Amsler, I. G., Jeker, B., Taleghani, B. M., Bacher, U., Betticher, D. C., Egger, T., Zander, T., Lüthi, J.-M., Novak, U., & Pabst, T. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1473577 · Cited by 16
Future Directions in Maintenance Therapy in Multiple Myeloma
Holstein, S. A., Suman, V. J., Hillengass, J., & McCarthy, P. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112261 · Cited by 17
Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation
Nishihori, T., Kar, S. M. A., Baz, R., Alsina, M., Harousseau, J., & Kharfan‐Dabaja, M. A. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.02.003 · Cited by 16
Self-citation
An old drug with a new future: bendamustine in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Vigna, E., Martino, M. V., Morabito, L., Lucia, E., Bossio, S., Stefano, L. D., Granata, T., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.837885 · Cited by 16
Evolving therapeutic paradigms for multiple myeloma: back to the future
Cherry, B. M., Korde, N., Kwok, M., Roschewski, M. J., & Landgren, O. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.717277 · Cited by 17
New pharmacotherapy options for multiple myeloma
Mina, R., Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1115016 · Cited by 17
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens
Maymani, H., Lin, P. Y., Saliba, R. M., Popat, U., Bashir, Q., Shah, N. D., Patel, K. K., Parmar, S., Kebriaei, P., Hosing, C. M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.009 · Cited by 16
Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents
Chen, Y., McCarthy, P. L., Hahn, T., Holstein, S. A., Ueda, M., Kröger, N. M., Bishop, M. R., & Lima, M. J. G. D. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0269-3 · Cited by 16
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
D’Agostino, M., Paoli, L. D., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.008 · Cited by 16
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Luoma, S., Anttila, P. M., Säily, M., Lundán, T., Heiskanen, J., Siitonen, T., Kakko, S., Putkonen, M., Ollikainen, H., Terävä, V., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03815-7 · Cited by 17
NCCN Guidelines Update for Multiple Myeloma
Anderson, K. C. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0190 · Cited by 15
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review
Sinit, R. B., Hwang, D. G., Vishnu, P., Peterson, J. F., & Aboulafia, D. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6286-9 · Cited by 15
Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma
George, L. L., Malik, M. N., Miller, E. J., Hicks, K., Khanam, R., Saterehaseman, A., McNichol, M. C., & Anwer, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.013 · Cited by 15
Novel immunomodulatory compounds in multiple myeloma
Saini, N. Y., & Mahindra, A. K. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.749235 · Cited by 15
Lenalidomide maintenance—perils of a premature denouement
Rajkumar, S. V. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100 · Cited by 15
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma
Brioli, A., Kaiser, M., Pawlyn, C., Wu, P., Gregory, W. M., Owen, R. G., Ross, F. M., Jackson, G. H., Cavo, M., Davies, F. E., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.760736 · Cited by 15
All transplantation-eligible patients with myeloma should receive ASCT in first response
Moreau, P., & Attal, M. (2014) · Hematology · doi:10.1182/asheducation-2014.1.250 · Cited by 15
Self-citation
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Nishihori, T., Song, J., & Shain, K. H. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0308-3 · Cited by 15
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto, P., & Montefusco, V. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1196127 · Cited by 15
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.003 · Cited by 15
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
Fazzi, R., Petrini, I., Giuliani, N., Morganti, R., Carulli, G., Palma, B. D., Notarfranchi, L., Galimberti, S., & Buda, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573156 · Cited by 15
DESIGN, MOLECULAR MODELING AND SYNTHESIS OF NEW IMMUNOMODULATORY AGENTS FOR BIOLOGICAL STUDIES
El‐Zahabi, M. A. (2021) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2021.187700 · Cited by 16
PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
Li, C., Sun, Y., Wang, J., Tang, L., Jiang, H., Guo, T., Liu, L., Wu, Y., Ai, L., Xia, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.599493 · Cited by 15
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 17
Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy
Stella, F., Pedrazzini, E., Agazzoni, M., Ballester, O., & Slavutsky, I. R. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1080833 · Cited by 15
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study
Robinson, A. A., Wang, J., Vardanyan, S., Madden, E., Hebroni, F., Udd, K. A., Spektor, T. M., Nosrati, J. D., Kitto, A., Zahab, M., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12748 · Cited by 15
Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents
Liew, W. K. M., Pacak, C. A., Visyak, N., Darras, B. T., Bousvaros, A., & Kang, P. B. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.07.040 · Cited by 15
Using Poisson–gamma model to evaluate the duration of recruitment process when historical trials are available
Minois, N., Lauwers‐Cancès, V., Savy, S., Attal, M., Andrieu, S., Anisimov, V. V., & Savy, N. (2017) · Statistics in Medicine · doi:10.1002/sim.7365 · Cited by 15
Self-citation
Immunomodulatory Agents for Multiple Myeloma
Minařík, J., & Ševčı́ková, S. (2022) · Cancers · doi:10.3390/cancers14235759 · Cited by 17
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S., & Bensinger, W. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.3 · Cited by 14
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation
Yalniz, F., Greenbaum, U., Pasvolsky, O., Milton, D. R., Kanagal‐Shamanna, R., Ramdial, J., Srour, S. A., Mehta, R. S., Alousi, A. M., Popat, U., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.015 · Cited by 14
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma
Kuroda, J., Nagoshi, H., Shimura, Y., & Taniwaki, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.829641 · Cited by 14

Authors: Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.-C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., & Harousseau, J.-L.
Affiliations: Hôpital Purpan (FR)
CHU Dijon Bourgogne (FR)
Hôpital Claude Huriez (FR)
Institut Paoli-Calmettes (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
Hôpital Saint-Antoine (FR)
Hôpital Pontchaillou (FR)
Centre Hospitalier Universitaire Vaudois (CH)
Centre Hospitalier Universitaire de Besançon (FR)
Hôpital Edouard Herriot (FR)
Institut Curie (FR)
ORCID: Attal, Michel
Caillot, Denis
Moreau, Philippe
Facon, Thierry
Hulin, Cyrille
Garderet, Laurent
Decaux, Olivier
Leyvraz, Serge
Vekemans, Marie-Christiane
Michallet, Mauricette
Dumontet, Charles
Roussel, Murielle
Leleu, Xavier
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1782-1791
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114138
OpenAlex: W2128084036
Semantic Scholar: c28c0ef900dcfd0347dbf26ecd97d5547f948a9a
Cited by: 1,155
References: 24
Citations by year: 2026: 32 · 2025: 36 · 2024: 43 · 2023: 61 · 2022: 70 · 2021: 85 · 2020: 79 · 2019: 68 · 2018: 83 · 2017: 98 · 2016: 108 · 2015: 86 · 2014: 102 · 2013: 133 · 2012: 68
FWCI: 82.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: lenalidomide, maintenance therapy, multiple myeloma, autologous stem cell transplantation, progression-free survival, event-free survival, secondary malignancies, peripheral neuropathy, young patients, residual disease
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks